In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scots say yes to BMS/Pfizer's Eliquis and BI's Trajenta

This article was originally published in Scrip

Executive Summary

Scotland's health technology appraisal body, the Scottish Medicines Consortium, has given the green light to Bristol-Myers Squibb/Pfizer's Eliquis (apixaban) for stroke prevention and Boehringer Ingelheim's Trajenta (linagliptin) for improving glyecamic control in type 2 diabetes patients.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC020360

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel